FDA grants Editors beta thalassemia therapy an orphan drug designation

The US Food and Drug Administration (FDA) Accept Designation of an orphan drug for EDIT-301, an experimental gene editing therapy for Editas Medicine to treat beta-thalassemia.

EDIT-301 is composed of CD34 + hematopoietic stem cells and progenitor cells obtained from the patient and is edited by the AsCas12a nuclease at the gamma globin gene (HBG1 and HBG2) promoters.

It has been analyzed to treat severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT).

The company plans to begin Phase I / II clinical trials of EDIT-301 in transfusion-dependent beta-thalassemia patients who are expected to be on medication by the end of this year.

James Mullen, Chairman, President and CEO of Editas Medicine, said: “Beta thalassemia is a catastrophic disease that leads to severe anemia, organ failure and premature death.

“Preparations are underway to begin Phase I / II clinical trials of EDIT-301, a potentially transformative drug for people with beta-thalassemia, and administration to the first patients in this year’s clinical trials. I’m looking forward to it. “

Beta thalassemia is a common autosomal recessive disorder whose mutations reduce or inhibit beta-globin expression.

Inadequate production of beta globin causes ineffective production of red blood cells, compensatory extramedullary hematopoiesis, and chronic hemolytic anemia due to red blood cell destruction.

Previously, EDIT-301 was designated by the FDA as a rare childhood disease to treat beta-thalassemia and SCD.

It is currently being analyzed in a RUBY clinical trial in patients with severe sickle cell disease.

April 2019, Editas and BlueRock Therapeutics collaborated Discover, develop and manufacture new drugs in the fields of oncology, neurology, cardiology and immunology.

The range of cell and gene therapies related to pharmaceutical technology is supported by Cytiva..

Editorial content is created independently and Highest standard Of the integrity of journalism. Topic sponsors are not involved in creating edited content.

Free white paper


Secure a bench-to-bedside cell therapy supply chain

The development of cell therapies is changing health care and bringing new hope to thousands of patients around the world. However, the vein-to-venous workflow of these therapies is not without challenges, many of which increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain of cell therapy and how to best reduce supply chain disruption.

By Cytiva Thematic

[無料のホワイトペーパーをダウンロード]By clicking the button, you agree to the terms of use and agree that your data will be used as described in the Cytiva Thematic Privacy Policy.

By downloading this white paper, we may share your information with our white paper partners / sponsors, and our white paper partners / sponsors may contact you directly with information about our products and services. Shall be acknowledged.

Please see us privacy policy Learn more about our services, information about your rights to your personal data, how to unsubscribe from future marketing communications, and how to use, process, and share your personal data. Our service is intended for corporate subscribers and ensures that the email address sent is the corporate email address. FDA grants Editors beta thalassemia therapy an orphan drug designation

Back to top button